Correlation of NLRP3 With Cognitive Dysfunction Early After Heart Valve Replacement Surgery

Correlation of NLRP3 With Cognitive Dysfunction Early After Heart Valve

The investigators decided to assess the prognostic value of NLRP3 inflammasome level in early after heart valve replacement surgery and whether it was related to postoperative cognitive dysfunction. Study population included 90 subjects. Neuropsychological tests were administrated one day before surgery and seven days after surgery. Before induction of anesthesia, before the end of the operation, 7 days after the operation, peripheral venous blood was sampled to measure IL-1B, IL-18 and NLRP3 inflammatory protein expression in peripheral blood monocytes. Analyze the data and draw conclusions.

Study Overview

Detailed Description

90 consecutive patients scheduled for mitral valve replacement or aortic valve replacement under moderate hypothermic CPB gave written informed consent and were enrolled in this study.

In the operating room, patients received routine monitoring. Systemic arterial blood pressure was measured via radial artery catheterization. After induction of anesthesia, a central venous catheter was inserted for monitoring central venous pressure (CVP) and fluid management. Baseline readings of hemodynamics were taken every 5 to 10 min after radial artery cannulation was completed.

Induction of anesthesia was performed with target-controlled infusion of propofol. All patients received an infused scheme of several steps that started from a target plasma concentration (Cp) of 0.5 mg/mL that was increased stepwise by 0.5 mg/mL until the patient fell asleep and maintain BIS at 40-60. The interval between each step was 3 min. After loss of consciousness, cisatracurium (0.2 mg/kg) and fentanyl (10-15 mg/kg) were infused in all groups. The trachea was intubated and the lungs were ventilated with oxygenenriched air (fraction of inspired oxygen 0.6) to an end-tidal carbon dioxide partial pressure of 35 to 45 mmHg. The propofol target Cp was adjusted according to BIS. Intermittent IV boluses of fentanyl (10-15 mg/kg) were administered according to blood pressure and heart rate (HR) at the following time points: before the skin incision, before the onset of CPB, and after separation from CPB, for a total dose of 40 to 50 mg/kg. All patients received infusion of cisatracurium at 0.1 mg/kg/h throughout the surgery.

Surgery was conducted on all patients via a standard median sternotomy approach. Porcine heparin was administered at a dose of 300 IU/kg and supplemented when required to maintain an activated coagulation time of at least 480 s during CPB. Heparin was neutralized with 1 mg of protamine/100 IU of heparin administered after separation from CPB. Body temperature was cooled to 30℃-32℃ on CPB (moderate hypothermia). All patients were treated with an intermittent antegrade infusion of cooled high-potassium blood cardioplegia during continuous aortic cross-clamping (ACC) using a nonpulsatile flow rate of 1.8 to 2.8 L/min/m2 and a membrane oxygenator to keep the mixed venous saturation at more than 75% during CPB. Phenylephrine (bolus, 20-100 mg) or epinephrine (0.1 mg/kg/min) or both were used to restore systemic vascular resistance, and MAP was maintained at a target range of 60 to 80 mmHg. Patients were warmed to a bladder temperature of 36.5℃ before separation from CPB, with the highest temperature not exceeding 37℃. Blood remaining in the CPB circuit and from the surgical field was collected in a cell-saving device. After centrifuging and washing, it was infused to the patient within 4 hours after CPB. Hematocrit was maintained at more than 25%, with the addition of blood as necessary. Insulin therapy was initiated during the surgery to treat serum blood glucose levels higher than 150 mg/dL. Hemodynamic (pre- or post-CPB) management aimed to keep MAP at 60 to 100 mmHg. Hypertension was treated with an additional bolus dose of fentanyl (0.2-0.3 mg) or with nitroglycerin (0.1-0.5 mg/kg/min or with both). Hypotension was treated with fluid intake (including crystalloids, colloids, and blood products) or vasoactive drug administration (phenylephrine IV, 20-100 mg or concomitant use of epinephrine, o 0.1 mg/min). The vasoactive drug dosage, fluid intake, and output (urine and blood loss) were recorded when the surgery was finished.

As the surgeons began to close the skin, a 0.08 mg/kg bolus dose of midazolam was given intravenously and the infusion of propofol was stopped. After the surgery, all patients were admitted to the surgical intensive care unit (ICU). The patients were extubated when they were able to sustain adequate spontaneous respiration and required minimal oxygen support, as reflected by normal arterial blood gas levels. The patients then were discharged from the ICU when they were hemodynamically stable with blood gas variables within the normal range and when they did not need inotropic or oxygen support. The tracheal extubation time and the length of the ICU stay were recorded. For all patients, hemodynamic measurements were made and recorded at the following times: Before induction of anesthesia, before skin incision, after sternotomy, at the cessation of CPB (CPB-cessation), and at 1 (Post-CPB 1 h), 2 (Post-CPB 2 h), and 4 (Post-CPB 4 h) hours after CPB. At pre-incision, CPB-cessation, Post-CPB 2 h, and PostCPB 4 h, the radial arterial blood was sampled for blood gas analysis, as well as blood glucose and lactic acid analyses. Before induction of anesthesia, at the end of the operation, 7 days after the operation, peripheral venous blood was sampled to measure IL-1B, IL-18 and NLRP3 inflammatory protein expression in peripheral blood monocytes.

Neuropsychological tests were administrated one day before surgery and seven days after surgery for all patients in a quiet place of the general wards. Neuropsychological tests included seven tests with nine subscales. Specific tests used were as follows: MMSE, Trail Making (A/B), Stroop Color- Word, Rey Auditory Verbal Learning Test, WAIS Digit Symbol Substitution Test, WAIS Digit Span, Verbal fluency test. Two psychologists carried out these tests. During the study phase, testing was performed and scored in a standardized manner in order to minimize inter-examiner difference. Repeat assessments for each patient were conducted by the same examiner. Parallel forms of tests were used in a randomized manner in sequential testing in order to minimize practice effect. Performance on each test was compared with cognitive test data of control subjects. A low test score was defined when the score was ≥ 2 SD lower than control subjects. For tests in which a higher score indicates decrement in performance, a score ≥ 2 SD higher than control subjects was considered as "low test score." Patients were defined as having preoperative cognitive impairment if they had low test scores on two or more tests.

For patients, preoperative scores were compared with postoperative test results, subtracted the average practice effect from these changes, and then divided the result by the control-subject SD to obtain a Z score for each test. The test results were adjusted so that a positive Z score indicated deterioration from the baseline test. The Z scores of all tests in an individual patient were then summarized and divided by the SD for this sum of Z scores in the control subjects, creating a combined Z score. A patient was defined as having POCD when two Z scores in individual tests or the combined Z score were 1.96 or more.

Statistical analysis A continuous outcome was expressed as the mean ± SE, while a categorical outcome was expressed as percentages or frequencies. Differences in continuous and categorical outcomes were tested using the one-way analysis of variance and Chi square analysis, respectively. The unpaired Student t test, paired T test, analysis of variance and Pearson correlation analysis were performed on normally distributed data. Case-control differences in nominal data were evaluated with the Chi square test. Multivariate Cox regression analysis was done for predictors of adverse events. The NLRP3 level, IL-1B, IL-18 and neurobehavioral scores were compared using ROC curves. Kaplan-Meier curves were used for correlation with POCD. All statistical analyses were performed with SPSS 21.0 (IBM Inc.) and P < 0.05 was considered signifcant.

Study Type

Observational

Enrollment (Actual)

75

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ningxia
      • Yinchuan, Ningxia, China, 750004
        • Department of Anesthesiology, General Hospital of Ningxia Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Elderly heart surgery patients

Description

Inclusion Criteria:

  • Patients were included if they had an American Society of Anesthesiologists status of II or III and older than 60 years old.

Exclusion Criteria:

  • A preoperative history of liver or kidney dysfunction, peripheral vascular disease, diabetes mellitus, or arterial hypertension;
  • Ischemic cerebrovascular disease;
  • A history of an acute or evolving myocardial infarction or presentation with a left ventricular ejection fraction (LVEF) of less than 45%;
  • Obesity (body mass index 430 kg/m2);
  • Moderate or severe atherosclerotic lesions in the ascending aorta or carotid artery stenosis confirmed by preoperative ultrasonography
  • Patients requiring re-exploration after surgery or a total CPB time more than 115 min
  • Patients requiring highdose pharmacologic support (phenylephrine 4 100 mg bolus, or epinephrine 4 0.1mg/kg/min or both) to maintain hemodynamic stability (mean arterial pressure [MAP] more than 60 mmHg)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The correlation between peripheral blood NLRP3 inflammasome level and incidence of postoperative cognitive dysfunction
Time Frame: The day before surgery, 7 days after surgery

Peripheral venous blood was sampled to measure NLRP3 inflammasome expression.

POCD was defined by Z scores that based on the neuropsychological tests, and then, get the incidence of POCD.

The method of Z scores is as follows: A patient was defined as having POCD when two Z scores in individual tests or the combined Z score were 1.96 or more.

Neuropsychological tests included MMSE(screening method); Trail Making (A/B); Stroop Color-Word; Rey Auditory Verbal Learning Test; WAIS Digit Symbol Substitution Test; WAIS Digit Span; Verbal fluency test.

Preoperative scores were compared with postoperative test results, subtracted the average practice effect from these changes, and then divided the result by the control-subject SD to obtain a Z score for each test. The Z scores of all tests in an individual patient were then summarized and divided by the SD for this sum of Z scores in the control subjects, creating a combined Z score.

The day before surgery, 7 days after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The correlation between peripheral blood IL-1B levels and incidence of postoperative cognitive dysfunction
Time Frame: At the end of the surgery, 7 days after surgery

Peripheral venous blood was sampled to measure IL-1B expression.

POCD was defined by Z scores that based on the neuropsychological tests, and then, get the incidence of POCD.

The method of Z scores is as follows: A patient was defined as having POCD when two Z scores in individual tests or the combined Z score were 1.96 or more.

Neuropsychological tests included MMSE(screening method); Trail Making (A/B); Stroop Color-Word; Rey Auditory Verbal Learning Test; WAIS Digit Symbol Substitution Test; WAIS Digit Span; Verbal fluency test.

Preoperative scores were compared with postoperative test results, subtracted the average practice effect from these changes, and then divided the result by the control-subject SD to obtain a Z score for each test. The Z scores of all tests in an individual patient were then summarized and divided by the SD for this sum of Z scores in the control subjects, creating a combined Z score.

At the end of the surgery, 7 days after surgery
The correlation between peripheral blood IL-18 levels and incidence of postoperative
Time Frame: At the end of the surgery, 7 days after surgery

Peripheral venous blood was sampled to measure IL-18 expression.

POCD was defined by Z scores that based on the neuropsychological tests, and then, get the incidence of POCD.

The method of Z scores is as follows: A patient was defined as having POCD when two Z scores in individual tests or the combined Z score were 1.96 or more.

Neuropsychological tests included MMSE(screening method); Trail Making (A/B); Stroop Color-Word; Rey Auditory Verbal Learning Test; WAIS Digit Symbol Substitution Test; WAIS Digit Span; Verbal fluency test.

Preoperative scores were compared with postoperative test results, subtracted the average practice effect from these changes, and then divided the result by the control-subject SD to obtain a Z score for each test. The Z scores of all tests in an individual patient were then summarized and divided by the SD for this sum of Z scores in the control subjects, creating a combined Z score.

At the end of the surgery, 7 days after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Gang Ma, doctor, Department of Anesthesiology General Hospital of Ningxia Medical University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2019

Primary Completion (Actual)

January 30, 2021

Study Completion (Actual)

January 30, 2021

Study Registration Dates

First Submitted

November 27, 2019

First Submitted That Met QC Criteria

December 5, 2019

First Posted (Actual)

December 10, 2019

Study Record Updates

Last Update Posted (Actual)

September 1, 2021

Last Update Submitted That Met QC Criteria

August 30, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Complications

Subscribe